Regenxbio Inc. outlined key catalysts expected in 2026 and reported positive long‑term functional outcomes in its lead Duchenne muscular dystrophy gene therapy program, according to the company. The firm said new Phase I/II data for RGX‑202 show durable treatment effects at 18 months post‑treatment, with patients surpassing expected disease progression benchmarks.
Regenxbio said that all patients treated at the pivotal dose in the AFFINITY DUCHENNE trial exceeded expected disease trajectory on the North Star Ambulatory Assessment, comparing favourably with historical models. Additional safety, biomarker and functional data are planned for presentation at a clinical conference in March 2026.
The company said it anticipates several regulatory and clinical readouts in 2026 that could support commercial launches between 2026 and 2028. These include continued enrollment in confirmatory studies and preparation for a biologics licence application filing with the U.S. Food and Drug Administration by mid‑year. Regenxbio noted in‑house manufacturing capacity and strategic partnerships as part of its commercial readiness efforts.
Regenxbio’s late‑stage pipeline encompasses multiple assets beyond Duchenne, including investigational gene therapies for rare diseases and retinal conditions. The company said that its broader portfolio is positioned for advancement in clinical and regulatory milestones throughout 2026, reflecting its strategy to bring one‑time gene therapies to patients with high unmet medical need.
